94-15749. Delegations of Authority and Organization; Center for Drug Evaluation and Research  

  • [Federal Register Volume 59, Number 124 (Wednesday, June 29, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-15749]
    
    
    [[Page Unknown]]
    
    [Federal Register: June 29, 1994]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 5
    
     
    
    Delegations of Authority and Organization; Center for Drug 
    Evaluation and Research
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the 
    regulations for delegations of authority relating to the list of FDA 
    officials in the Center for Drug Evaluation and Research (CDER), Office 
    of Generic Drugs (OGD), with authority to perform all the functions of 
    the Commissioner of Food and Drugs with respect to approval of 
    supplemental applications. This action is being taken to reflect a 
    reorganization in OGD and to ensure the accuracy of the regulation.
    
    EFFECTIVE DATE: June 29, 1994.
    
    FOR FURTHER INFORMATION CONTACT: Ellen R. Rawlings, Division of 
    Management Systems and Policy (HFA-340), Food and Drug Administration, 
    5600 Fishers Lane, Rockville, MD 20857, 301-443-4976.
    
    SUPPLEMENTARY INFORMATION: FDA is amending the regulations in Sec. 5.80 
    Approval of new drug applications and their supplements (21 CFR 5.80) 
    to change the title of Associate Director for Labeling and Professional 
    Support, OGD, to Director, Division of Labeling and Program Support in 
    Sec. 5.80(e). In addition, the title of Deputy Director, Division of 
    Labeling and Program Support is being added to those authorized in 
    Sec. 5.80(e) to carry out the Commissioner's authorities described in 
    that section. These changes are being made to reflect a minor 
    reorganization in OGD.
        Further redelegation of the authority delegated is not authorized. 
    Authority delegated to a position by title may be exercised by a person 
    officially designated to serve in such position in an acting capacity 
    or on a temporary basis.
    
    List of Subjects in 21 CFR Part 5
    
        Authority delegations (Government agencies), Imports, Organization 
    and functions (Government agencies).
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs, 21 CFR part 
    5 is amended as follows:
    
    PART 5--DELEGATIONS OF AUTHORITY AND ORGANIZATION
    
        1. The authority citation for 21 CFR part 5 continues to read as 
    follows:
    
        Authority: 5 U.S.C. 504, 552, App. 2; 7 U.S.C. 138a, 2271; 15 
    U.S.C. 638, 1261-1282, 3701-3711a; secs. 2-12 of the Fair Packaging 
    and Labeling Act (15 U.S.C. 1451-1461); 21 U.S.C. 41-50, 61-63, 141-
    149, 467f, 679(b), 801-886, 1031-1309; secs. 201-903 of the Federal 
    Food, Drug, and Cosmetic Act (21 U.S.C. 321-394); 35 U.S.C. 156; 
    secs. 301, 302, 303, 307, 310, 311, 351, 352, 361, 362, 1701-1706, 
    2101, 2125, 2127, 2128 of the Public Health Service Act (42 U.S.C. 
    241, 242, 242a, 242l, 242n, 243, 262, 263, 264, 265, 300u-300u-5, 
    300aa-1, 300aa-25, 300aa-27, 300aa-28); 42 U.S.C. 1395y, 3246b, 
    4332, 4831(a), 10007-10008; E.O. 11490, 11921, and 12591; secs. 312, 
    313, 314 of the National Childhood Vaccine Injury Act of 1986, Pub. 
    L. 99-660 (42 U.S.C. 300aa-1 note).
    
        2. Section 5.80 is amended by revising paragraph (e) to read as 
    follows:
    
    
    Sec. 5.80  Approval of new drug applications and their supplements.
    
    * * * * *
        (e) The Director and Deputy Director, Division of Labeling and 
    Program Support, OGD, are authorized to perform all the functions of 
    the Commissioner of Food and Drugs with respect to approval of 
    supplemental applications to abbreviated new drug applications, 5S 
    applications, or 505(b)(2) applications for drugs for human use that 
    are described in Sec. 314.70(b)(3) and (c)(2)(i) through (c)(2)(iv) of 
    this chapter. Authority to approve supplements that require in vivo 
    bioavailability studies or in vivo study waiver requests is not 
    included in this paragraph.
    * * * * *
    
        Dated: June 23, 1994.
     Micheal R. Taylor,
     Deputy Commissioner for Policy.
    [FR Doc. 94-15749 Filed 6-28-94; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
06/29/1994
Department:
Food and Drug Administration
Entry Type:
Uncategorized Document
Action:
Final rule.
Document Number:
94-15749
Dates:
June 29, 1994.
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: June 29, 1994
CFR: (2)
21 CFR 5.80(e)
21 CFR 5.80